" class="no-js "lang="en-US"> Drug Development Archives - Page 3 of 33 - Medtech Alert
Friday, March 31, 2023

Sort by:


Top Post

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]

China National Medical Products Administration Accepts Regulatory Submission for Nucala (mepolizumab) in Severe Eosinophilic Asthma

GSK today announced that the China National Medical Products Administration has accepted for review a […]

Accord Healthcare Adds Generic Drug Approved for the Treatment of Relapsing MS

Accord Healthcare, a leading generic pharmaceutical company, has added Teriflunomide to its portfolio of oral […]

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

Pfizer has announced the US Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the […]

AnnJi Pharmaceutical Announced a Licensing Agreement With Avenue Therapeutics For The Treatment Of Kennedy's Disease

AnnJi Pharmaceutical has entered into an exclusive license agreement with Avenue Therapeutics for the development and […]

AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B

AusperBio has announced the completion of the first cohort dosing in a Phase 1 clinical […]

FDA Accepts Supplemental New Drug Application for Jardiance® for Children 10 years and Older with Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for […]

Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs […]

Personalis Selected for Clinical Research by AstraZeneca After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

Personalis, a leader in advanced genomics for precision oncology, today announced it will continue its […]

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) accepted for Priority […]

  1. Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
  2. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
  3. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  4. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  5. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more